12 March 1999
Hyperhomocysteinemia as A Risk Factorfor Cardiovascular Diseases.The Association of Hyperhomocysteinemia with Diabetes Mellitus and Renal Transplant Recipients
Marcin W Socha, Malgorzata J Polakowska, Koryna Socha-Urbanek, Piotr FiedorAnn Transplant 1999; 4(1): 11-19 :: ID: 497432
Abstract
Hyperhomocysteinemia has been recognised as an independent risk factor for cardiovascular, cerebrovascular and peripheral artery disease. There is strong evidence suggesting that hyperhomocysteinemia accelerates the process of atherogenesis. Possible explanations for this will be shortly reviewed. Recently a growing interest has been focused on the association of hyperhomocysteinemia with diabetes mellitus and with chronic renal disease, including renal transplant recipients. Some clinicalaspects of this occurrence, such as interactions with insulin, metformin, and cyclosporine and also with some vitamins, will be described. The issue of hyperhomocysteinemia in heart transplant patients will also be mentioned. Last of all, the interaction of homocysteine concentration with some beverages will be considered.
Keywords: homocysteine, Hyperhomocysteinemia, Diabetes Mellitus, Organ Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






